Kefah Mokbel

1 week ago | bpspubs.onlinelibrary.wiley.com | Mariam Rizk |Kefah Mokbel

Dear Editor, We read with interest the recent study investigating a potential association between third-generation aromatase inhibitors (AIs) and dementia using VigiBase data [1]. While the authors present a compelling case for further exploration of this link, several key methodological limitations were either inadequately discussed or overlooked. First, pharmacovigilance databases like VigiBase are inherently prone to reporting bias.